Status: MediSieve’s frontline product targets IL-6 driven hyperinflammation, present in many patients including those suffering from sepsis, cytokine release syndrome (a common side-effect of CAR-T cell immunotherapy), and COVID-19. The beads for IL-6 are at the pre-clinical stage. We expect to start randomised control trials in 2021.